Novartis is reimagining medicine to improve people's lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines. About 110,000 people of more than 140 nationalities work at Novartis.
Learn More About Specifically Targeting the ABL Myristoyl Pocket (STAMP) in CML
View our broad research portfolio with innovative compounds in all phases of development.
Novartis is uniquely positioned to lead the next wave of novel investigational treatments through our strengths in 4 therapeutic platforms: targeted therapy, radioligand therapy, cell & gene therapy, and immunotherapy.
At Novartis, we are committed to the pursuit of cutting-edge medicines and are working to transform what it means to live with blood cancers and serious blood disorders.
